Home » Stocks » NBRV

Nabriva Therapeutics PLC (NBRV)

Stock Price: $1.45 USD -0.06 (-3.67%)
Updated Apr 19, 2021 12:05 PM EDT - Market open
Market Cap 52.18M
Revenue (ttm) 5.03M
Net Income (ttm) -69.48M
Shares Out 34.79M
EPS (ttm) -5.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $1.45
Previous Close $1.50
Change ($) -0.06
Change (%) -3.67%
Day's Open 1.47
Day's Range 1.44 - 1.50
Day's Volume 488,847
52-Week Range 1.40 - 12.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- SIVEXTRO now available under Nabriva's National Drug Code

4 days ago - GlobeNewsWire

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: ADBE, CRDF, KNSL, VEEV
5 days ago - Zacks Investment Research

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: ADBE, KNSL, VEEV, YEXT
2 weeks ago - Zacks Investment Research

DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

2 weeks ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

2 weeks ago - GlobeNewsWire

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives-

1 month ago - GlobeNewsWire

Nabriva Therapeutics (NBRV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 month ago - Zacks Investment Research

DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

1 month ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

1 month ago - GlobeNewsWire

CHICAGO, Feb. 26, 2021 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ) LARRY ENRIQUEZ v. NABRIVA ) Case No. 1:19-cv-04183-VM THERAPEUTICS PLC, et al. ) Honorable Victor Marr...

1 month ago - PRNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

1 month ago - GlobeNewsWire

Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country

1 month ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

2 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

3 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

4 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

4 months ago - GlobeNewsWire

- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support

4 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

5 months ago - GlobeNewsWire

Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

-Relaunch of Xenleta® and Sivextro® commenced in late September-  

5 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

5 months ago - GlobeNewsWire

-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of p...

6 months ago - GlobeNewsWire

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship

7 months ago - GlobeNewsWire

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...

8 months ago - GlobeNewsWire

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...

8 months ago - GlobeNewsWire

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

8 months ago - Zacks Investment Research

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years

8 months ago - GlobeNewsWire

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

8 months ago - GlobeNewsWire

-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

9 months ago - GlobeNewsWire

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

9 months ago - Zacks Investment Research

DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

9 months ago - GlobeNewsWire

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Conduct Onsite ...

9 months ago - GlobeNewsWire

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

10 months ago - Zacks Investment Research

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

10 months ago - GlobeNewsWire

Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acq...

11 months ago - GlobeNewsWire

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP Results support Xenleta as an empiric, short-course monotherapy replace...

11 months ago - GlobeNewsWire

Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...

1 year ago - GlobeNewsWire

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...

1 year ago - GlobeNewsWire

Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Nabriva Therapeutics' (NBRV) CEO Ted Schroeder on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DUBLIN, Ireland, March 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...

1 year ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

1 year ago - Zacks Investment Research

About NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well a... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2015
CEO
Theodore Schroeder
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
NBRV
Full Company Profile

Financial Performance

In 2020, NBRV's revenue was $5.03 million, a decrease of -46.98% compared to the previous year's $9.48 million. Losses were -$69.48 million, -16.05% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 315.22% from the latest price.

Price Target
$6.00
(315.22% upside)
Analyst Consensus: Buy